<i>IMPORTANT</i> : Check box if Confidential Treatment is requested Registered Entity Identifier Code (optional): <u>21-500</u> Organization: <u>Chicago Mercantile Exchange Inc. ("CME")</u>					
			Filing	g as a: DCM SEF DCO	SDR
			Pleas	e note - only ONE choice allowed.	
	g Date (mm/dd/yy): <u>11/05/21</u> Filing Description: ing's Credit Risk Assessment Methodology Policy	Modifications to CME			
SPEC	TIFY FILING TYPE				
	note only ONE choice allowed per Submission.				
Orgar	ization Rules and Rule Amendments				
\square	Certification	§ 40.6(a)			
	Approval	§ 40.5(a)			
	Notification	§ 40.6(d)			
	Advance Notice of SIDCO Rule Change	§ 40.10(a)			
	SIDCO Emergency Rule Change	§ 40.10(h)			
	Numbers: <u>See filing.</u> Product Please note only ONE p	roduct per Submission.			
	Certification	§ 40.2(a)			
	Certification Security Futures	§ 41.23(a)			
	Certification Swap Class	§ 40.2(d)			
	Approval	§ 40.3(a)			
	Approval Security Futures	§ 41.23(b)			
	Novel Derivative Product Notification	§ 40.12(a)			
	Swap Submission	§ 39.5			
	al Product Name:				
Produ	ct Terms and Conditions (product related Rules and Rule A	Amendments)			
	Certification	§ 40.6(a)			
	Certification Made Available to Trade Determination	§ 40.6(a)			
	Certification Security Futures	§ 41.24(a)			
	Delisting (No Open Interest)	§ 40.6(a)			
	Approval	§ 40.5(a)			
	Approval Made Available to Trade Determination	§ 40.5(a)			
	Approval Security Futures	§ 41.24(c)			
	Approval Amendments to enumerated agricultural products	§ 40.4(a), § 40.5(a)			
	•••••••••••••••••••••••••••••••••••••••				

Official Name(s) of Product(s) Affected:



Timothy J. Maher Chief Compliance Officer CME Clearing

November 5, 2021

VIA ELECTRONIC PORTAL

Mr. Christopher J. Kirkpatrick Office of the Secretariat Commodity Futures Trading Commission Three Lafayette Centre 1155 21st Street, N.W. Washington, DC 20581

Re: CFTC Regulation 40.6(a) Certification. Modifications to CME Clearing's Credit Risk Assessment Methodology Policy. CME Submission No. 21-500

Dear Mr. Kirkpatrick:

Pursuant to Commodity Futures Trading Commission ("CFTC" or "Commission") Regulation 40.6(a), Chicago Mercantile Exchange Inc. ("CME Clearing" or "Exchange") certifies to the Commission modifications to the CME Clearing's Credit Risk Assessment Methodology Policy (the "CAM") (collectively, the "Rule Amendments") effective on November 23, 2021.

Specifically, CME Clearing, as a registered derivatives clearing organization, maintains the CAM consistent with CFTC Regulation 39.13(e) which details the processes for the credit risk assessments and the methodology for establishing internal credit ratings to mitigate and manage counterparty credit risk exposure. The CAM is established by CME Clearing and approved by the Clearing House Oversight Committee.

Portions of the Rule Amendments are substantive in nature and required the Committee's approval as part of the annual review. While substantive in nature, the Rule Amendments do not have a significant impact on the risk profile of the Clearing House.

The Rule Amendments provide, as an additional qualitative consideration, a leverage category to the Hedge Fund Rating Considerations and Scorecard. Enhancements are being implemented to the Bank Rating Scorecard. CME Clearing does not believe this enhancement will materially change the rating distribution of bank counterparties. Non-substantive changes are being made to Sections 7.4.1.1 (Operating Environment & Industry Profile), 7.4.1 (Qualitative Considerations), 16.4 (Hedge Fund Scorecard), 7.4.2 (Weights), and 16.10 (C10 Proprietary Trading Firm Scorecard).

CME Clearing reviewed the derivatives clearing organization core principles ("Core Principles") as set forth in the Commodity Exchange Act ("CEA" or "Act") and identified that the Rule Amendments may have some bearing on the following principles:

• <u>DCO Core Principle D – Risk Management:</u> The Rule Amendments enhance the metrics and criteria of the CAM in assessing counterparty credit risk exposure to manage the risks associated with discharging the responsibilities of the derivatives clearing organization.

CME has requested confidential treatment with respect to the Rule Amendments, which has been submitted concurrently with this self-certification. CME Clearing certifies that the Rule Amendments comply with the Act and regulations thereunder. There were no substantive opposing views to this action.

If you require any additional information regarding this submission, please contact me at 312-930-2730 or via email at <u>timothy.maher@cmegroup.com</u>. Please reference CME Submission No. 21-500 in any related correspondence.

Sincerely,

/s/Timothy Maher Chief Compliance Officer CME Clearing

Attachment Exhibit A – Modifications to the CME Clearing Credit Risk Assessment Methodology Policy (attached under separate cover) (blackline format) (confidential treatment requested)